SCHEMBL7218170

SCHEMBL7218170

CCOC(=O)c1ccc(C=C(C)c2cc3c(cc2C)OC(C)(C)CC3(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 16/20 0.49
RARG P13631 14/20 0.49
RARA P10276 12/20 0.49
RXRA P19793 10/20 0.49
RXRB P28702 3/20 0.49
RXRG P48443 3/20 0.49
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
CYP26A1 O43174 1/20 0.36
GMNN O75496 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7218168 1.00 RARB (0.49) RARBRARGRARARXRARXRB
SCHEMBL7217799 0.86 RARB (0.66) RARBRARGRARARXRARXRB
SCHEMBL9078166 0.86 RARB (0.66) RARBRARGRARARXRARXRB
SCHEMBL7217796 0.86 RARB (0.66) RARBRARGRARARXRARXRB
SCHEMBL10841202 0.86 RARB (0.62) RARBRARGRARARXRARXRB
SCHEMBL10841205 0.86 RARB (0.62) RARBRARGRARARXRARXRB
SCHEMBL8460713 0.82 RARA (0.58) RARBRARGRARARXRARXRB
SCHEMBL7224258 0.82 RARB (0.72) RARBRARGRARARXRARXRB
SCHEMBL7224256 0.82 RARB (0.72) RARBRARGRARARXRARXRB
SCHEMBL10844840 0.80 RARB (0.65) RARBRARGRARARXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6624188-B1 Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and ALLERGAN, INC. 2003-09-23 US disclosed
US-5324840-A Skin disorders ALLERGAN, INC. (US) 1994-06-28 US disclosed